维康药业 (300878)

Zhejiang Wecome Pharmaceutical Company Limited

ASZ

Tags

Low Safety ScoreInnovative DrugsPharmaceutical ManufacturingMicro and Small Cap StocksPrivate HospitalsHepatitis ConceptMargin Trading and Securities Lending

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 14479.03
  • Circulating A-Shares(W): 14412.40
  • Earnings Per Share(RMB): -0.8554
  • Net Assets Per Share(RMB): 7.0027
  • Operating Revenue(W RMB): 15131.78
  • Total Profit(W RMB): -11201.68
  • Net Profit Attributable to Parent(W RMB): -12385.46
  • Net Profit Growth Rate(%): -380.87
  • Weighted Return on Equity(%): -11.4000
  • Operating Cash Flow Per Share(RMB): 0.2970
  • Undistributed Profit Per Share(RMB): 1.1960
  • Capital Reserve Per Share(RMB): 4.7017

2. Main Business

The main business covers:

  • R&D, production and sales of modern Chinese medicine and Western medicine
  • Retail chain and other distribution business of pharmaceutical commercial products

3. Company Basic Information

  • Company Name: Zhejiang Wecome Pharmaceutical Company Limited
  • Listing Date: 2020-08-24
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 2 Suisong Road, Lishui Economic Development Zone, Zhejiang Province, China
  • Website: www.zjwk.com
  • Company Profile：On February 5, 2015, the shareholders' meeting of Zhejiang Wecome Pharmaceutical Co., Ltd. resolved to approve the overall change of Wecome Limited into a joint stock company based on the audit and evaluation date of January 31, 2015. On March 8, 2015, Tianjian Certified Public Accountants (Special General Partnership) issued the audit report numbered "Tianjian Audit [2015] No. 1667", stating that as of January 31, 2015, the audited net assets of Wecome Limited were 98.1597 million yuan. On March 21, 2015, Kunyuan Asset Appraisal Co., Ltd. issued the asset appraisal report "Kunyuan Appraisal Report [2015] No. 95", stating that as of January 31, 2015, the appraised value of the net assets of Wecome Limited was 114.3558 million yuan. On March 21, 2015, the shareholders' meeting of Wecome Limited resolved to confirm the audit report "Tianjian Audit [2015] No. 1667" issued by Tianjian Certified Public Accountants (Special General Partnership); and reviewed and approved the share conversion plan. The audited net assets of Zhejiang Wecome Pharmaceutical Co., Ltd. as of January 31, 2015 were 98.1597 million yuan, of which 60 million yuan was converted into the registered capital of the joint stock company according to the shareholders' contribution ratio, with a par value of 1 yuan per share, totaling 60 million shares, and the share conversion premium of 38.1597 million yuan was included in the capital reserve. On March 23, 2015, Tianjian Certified Public Accountants issued the capital verification report "Tianjian Verification [2015] No. 63", stating that as of March 22, 2015, Zhejiang Wecome Pharmaceutical Co., Ltd. (in preparation) had received the audited net assets of 98.1597 million yuan as of January 31, 2015 from all contributors, converted into 60 million shares, with the excess included in the capital reserve. Zhejiang Wecome Pharmaceutical Co., Ltd. completed the industrial and commercial registration at the Lishui Administration for Industry and Commerce on March 30, 2015, and obtained the business license with the registration number 331100000026424.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Lishui Shunze Investment Management Partnership (Limited Partnership) General Legal Person 592.32 4.11
2 Zhejiang Wecome Pharmaceutical Co., Ltd. Repurchase Special Securities Account General Legal Person 273.90 1.90
3 J. P. Morgan Securities PLC - Proprietary Funds QFII 47.44 0.33

5. Concept Sectors

  • Private Hospitals
  • Hepatitis Concept
  • Innovative Drugs
  • Margin Trading & Securities Lending
  • Consecutive Losses
  • Low Safety Score
  • Micro & Small Cap Stocks

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information